(MENAFN- ProactiveInvestors) Imugene () is preparing to initiate this year the clinical program for its Her-Vaxx peptide vaccine a B-cell based immunotherapy for HER-2 positive gastric & breast cancer.
Her-Vaxx has potential to improve upon Roche’s blockbuster Herceptin drug that generated annualised sales of $6.9 billion and targets the same biomarker.
It was developed by one of Europe’s leading cancer institutes with about $10 million already invested in the technology.
Managing director Charles Walker outlined these points and many others at the February 2015 Proactive Investors Melbourne / Sydney Luncheons.
The full presentation can be ACCESSED HERE.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.